While statins have transformed cardiovascular disease prevention, patients with a lesser-known type of lipid disease called elevated lipoprotein(a) (Lp[a]) face unique challenges. Recent clinical trials exploring Lp(a)-targeting medications show promise, yet proactive screening practices vary. Cynthia Miller, MD, MPH, FACP, Vice President, Medical Director, sits down with DocWire News and shares insights on the significance of early Lp(a) screening, strategies to enhance preventative cardiology, and optimize patient care.
